Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10815482-B2

Patent

Publication Date

2020-10-27

Expiration Date


Abstract

The present invention relates to chirally controlled oligonucleotides of select designs, chirally controlled oligonucleotide compositions, and methods of making and using the same. In some embodiments, a provided chirally controlled oligonucleotide composition provides different cleavage patterns of a nucleic acid polymer than a reference oligonucleotide composition. In some embodiments, a provided chirally controlled oligonucleotide composition provides single site cleavage within a complementary sequence of a nucleic acid polymer.

Core Innovation

The disclosure relates to chirally controlled oligonucleotide compositions enriched relative to substantially racemic preparations. The compositions comprise oligonucleotides sharing a common base sequence and length, a common pattern of backbone linkages, and a defined common pattern of backbone chiral centers. The common base sequence is complementary to a characteristic sequence element defining a target allele relative to other alleles.

The composition specifies an Rp(Sp)2 backbone chiral pattern from 5′ to 3′ that directs cleavage two base pairs downstream of that motif. Target-allele transcripts are cleaved within five base pairs upstream or downstream of the characteristic sequence element and undergo greater suppression than transcripts of another allele. The background section is omitted in the provided content, leaving the specific problem not explicitly described in patent.

The disclosure characterizes modified oligonucleotide cleavage kinetics, metabolic stability, FOXO1 mRNA levels, and sequence discrimination between mutant and wild-type Huntington alleles. Iterative synthesis utilizes coupling, capping, phosphorus-linkage modification, and deblocking [procedural detail omitted for safety] with structural substituent groups. Backbone stereochemistry alters RNase H cleavage efficiency, cleavage sites, and duration of knockdown.

Claims Coverage

The claims identify one independent claim covering allele-specific suppression of transcripts using a chirally controlled oligonucleotide composition across four inventive features.

Chirally controlled oligonucleotide composition enrichment

The composition comprises oligonucleotides of a particular type characterized by a common base sequence and length, a common pattern of backbone linkages, and a common pattern of backbone chiral centers, enriched relative to a substantially racemic preparation having the same base sequence and length.

Target allele-defining sequence complementarity

The common base sequence is or comprises a sequence complementary to the characteristic sequence element that defines the target allele relative to another allele.

Backbone chiral pattern and cleavage site specification

The common pattern of backbone chiral centers comprises, from 5′ to 3′, Rp(Sp)₂, and the composition provides a cleavage site two base pairs downstream of that Rp(Sp)₂ pattern.

Preferential target-allele cleavage and suppression

When contacted with a system comprising transcripts of both alleles, target-allele transcripts are cleaved at a site within five base pairs downstream or upstream of the characteristic sequence element and are suppressed at a greater level than transcripts of the other allele.

The independent claim combines an enriched, chirally controlled oligonucleotide composition with an allele-complementary sequence and a specified Rp(Sp)₂ backbone chiral pattern to direct cleavage positioning and achieve greater suppression of target-allele transcripts relative to another allele.

Stated Advantages

Target-allele transcripts are suppressed at a greater level than transcripts of another allele, with a dependent claim specifying suppression at least two-fold greater.

Strategically positioned chiral motifs tune nucleic acid cleavage patterns, produce altered and more focused cleavage, and enhance discrimination between mutant and wild-type transcripts compared to stereorandom oligonucleotides.

Backbone stereochemical control improves cleavage rates and turnover, nuclease and serum stability, knockdown duration, and siRNA potency.

Capping reduces n−1 impurities and facilitates purification, particularly for longer oligonucleotides.

Durable ApoB suppression is provided by stereochemically defined oligonucleotides.

Documented Applications

Allele-specific suppression of transcripts from a target nucleic acid sequence when multiple alleles exist in a population, including selective suppression of alleles distinguished by a SNP or mutation such as mutant and wild-type Huntingtin transcripts.

Cleavage, turnover, stability, and knockdown assays targeting FOXO1 mRNA, ApoB mRNA, and PCSK9.

Potential therapeutic applications to diseases associated with mutations or disease-associated alleles, including cancer and inherited disorders.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.